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AbstrACt
Objective To explore the separate and joint 
associations of childhood adversities and 5-HTTLPR 
polymorphism as risk factors for substance use 
disorders among adults.
Design Retrospective case-control study.
setting Cases from the substance unit and controls from 
a representative sample of the adult general population in 
the metropolitan area of Murcia (Spain).
Participants Cases were defined as outpatients 18 
years old or older currently in the treatment for alcohol, 
opioids or cocaine use disorders in the clinical unit. 
Controls were randomly selected among individuals 
without substance use disorders who participated in the 
Psychiatric Enquiry to General Population in Southeast 
Spain-Murcia (PEGASUS-Murcia) project, a cross-
sectional study of a representative sample of the adult 
general population. In all, 142 cases and 531 controls 
were interviewed and a subsample of 114 cases (80.3%) 
and 329 controls (62%) provided a biological sample.
Exposure A history of 12 childhood adversities, lifetime 
mental disorders and sociodemographic variables was 
assessed with the Composite International Diagnostic 
Interview (CIDI)version 3.0). Buccal swabs were obtained 
to genotype the 5-HTTLPR polymorphism with the biallelic 
and the triallelic classification.
Main outcome and measure Multivariable logistic 
regression models were performed to estimate adjusted 
ORs and 95% CI.
results Childhood adversities were associated with an 
elevated risk of substance use disorders (OR=5.77, 95% CI 
3.46 to 9.61). Homozygotes for the short allele of the 
5-HTTLPR polymorphism also showed the elevated risk 
of substance use disorders for the biallelic and triallelic 
classification: (1.97 (1.10 to 3.55) and 2.01 (1.11 to 
3.64), respectively). No evidence for gene × environment 
interactions was found.
Conclusions Childhood adversities and the 5-HTTLPR 
polymorphism are involved in the aetiology of 
substance use disorders though findings exploring 
the existence of a gene–environment interaction were 
inconclusive.
IntrODuCtIOn
Substance use disorders (SUD) constitute 
one of the major public health issues around 
the world,1 2 and are major contributors 
to burden of disease3 with greater risk of 
disability and mortality.4 5 SUDs are consid-
ered a highly multifactorial syndrome with 
a wide diversity of biological, psychological 
and sociocultural risk factors acting and 
interacting throughout their development.6 
SUDs have been described as moderately to 
highly heritable.7–9 One of the studied genes 
is the polymorphism in the promoter region 
of the serotonin transporter gene (SLC6A4) 
and its interest is related to its potential role 
strengths and limitations of this study
 ► In this case-control study, controls were randomly 
selected among a representative sample of the gen-
eral population without any substance use disorders 
from the same metropolitan area of Murcia (Spain).
 ► A careful screening for other mental disorders, per-
formed in both cases and controls using a struc-
tured clinical interview, the Composite International 
Diagnostic Interview 3.0, and a comprehensive 
number of variables was controlled in the multivar-
iate analyses.
 ► Quality genetic controls and the biallelic and triallel-
ic approaches to the 5-HTTLPR polymorphism were 
tested.
 ► Statistical power may be insufficient to detect gene–
environment interactions of the modest effect.
 ► Only a subgroup of participants provided biologi-
cal samples, but no major differences with regard 
to sociodemographic variables, number of lifetime 
mental disorders, principal substance of abuse and 
exposure to childhood adversities were found when 
they were compared with those who provided them.
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in drug consumption dependent on exposure to stress 
(see Goldman et al10 for a comprehensive review).
The serotonin transporter protein is the presynaptic 
neuronal reuptake site for serotonin and has been linked 
to the mechanism of action of several drugs.11 The 
promoter activity of the SLC6A4 gene, located at 17q11.1–
q12, could be modified by sequential elements within 
the proximal five regulatory region, designated as the 
serotonin transporter gene-linked polymorphic region 
(5-HTTLPR). The less frequent short (S) allele, associ-
ated with lower transcriptional efficiency compared with 
the more frequent long (L) allele,12 has been related to 
the increased risk of a range of mental health outcomes 
or disorders13–16 and, specifically to alcohol, heroin and 
cocaine dependence.11 However, evidence of the rela-
tion between the 5-HTTLPR polymorphism and SUDs is 
conflicting. Four meta-analyses have examined the associ-
ation between the 5-HTTLPR polymorphism and SUDs. 
The first meta-analysis found a modest association of the 
S allele with individuals diagnosed with alcohol depen-
dence, and a greater association with individuals with a 
comorbid psychiatric condition.17 These results highlight 
the importance of measuring comorbid psychiatric condi-
tions to control for their potential moderating effect in the 
association of the polymorphism with SUDs. The second 
meta-analysis detected a potential publication bias.18 The 
third showed a significant association of SUDs (including 
alcohol, heroin and cocaine dependence) with the poly-
morphism.11 Finally, the most recent meta-analysis did 
not find an overall association with alcohol dependence, 
but highlighted several methodological limitations in 
published studies19 including: inconsistencies in the 
screening of highly comorbid psychiatric disorders, lack 
of an adequate control group as many of the studies relied 
on convenience samples rather than population-based 
controls, insufficient description of genotyping methods 
and heterogeneity in case definition.
Other explanations of the heterogeneity of published 
results might stem from the existence of different classifi-
cations of the 5-HTTLPR polymorphism and gene–envi-
ronment (GxE) interactions. The description of a third 
functional allele (LG)
20 with an equivalence in expression 
to the S allele13 allowed triallelic genotyping or functional 
reclassification on the basis of lower and higher levels of 
expression21 22 with LG and S classified as S’, and LA as L’. 
Few studies have been published with this functional clas-
sification suggesting either a positive and significant23 or 
a non-significant effect24 associated with S’S’. Moreover, 
possible G×E interactions between traumatic life events 
and the polymorphism have been described.25–27 Child-
hood adversities (CAs) seem to be a good candidate for 
G×E interactions.28 The adversities analysed included: 
childhood neglect,29 30 maltreatment,31 poor mother–
child relations and family functioning.32 Results suggested 
positive G×E interactions in predicting early onset or 
adolescent alcohol use,31 32 increased susceptibility to 
experiment with illicit drugs29 or a significant moderating 
effect on cannabis use, but not on alcohol use problems.30 
The heterogeneity of findings underscores the necessity 
of new studies to clarify the implications of the 5-HTTLPR 
polymorphism in SUDs.
The aims of the current research are to replicate, in 
a case-control study, the association between CAs and 
the 5-HTTLPR polymorphism as determinants of SUDs 
in adults, and to explore potential G×E interactions on 




The current case-control study described in accordance 
with the Strengthening The Reporting of Genetic Associ-
ation Studies (STREGA) guidelines, an extension of the 
Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines for a candidate 
gene study.33 Two signed informed consents, one for the 
interview and the other for the collection of biological 
samples, were obtained from all participants.
Patient and public involvement
There was no patient or public involvement in the design 
or planning of this study.
selection of participants
Inclusion criteria for cases were being at least 18 years old 
currently receiving outpatient treatment for an alcohol, 
heroin or cocaine use disorder in the Substance Abuse 
Center, the main substance use treatment facility in the 
Murcia metropolitan area (775 000 inhabitants). Exclu-
sion criteria were being unable to understand Spanish 
or having a physical or mental condition that precluded 
them from being interviewed. Cases were selected and 
interviewed between February 2014 and March 2014. A 
control:case ratio of approximately 3:1 was previously 
determined to achieve a sufficient number of controls to 
allow for powerful calculations while balancing the cost of 
genetic analyses. Controls were selected from the partici-
pants of the Psychiatric Enquiry to General Population in 
Southeast Spain (PEGASUS)-Murcia project, a cross-sec-
tional study that was part of WHO World Mental Health 
survey initiative.34 It was designed to carry out face-to-face 
interviews with a representative sample of non-institution-
alised adults in the general population of the Region of 
Murcia. Inclusion criteria for controls were being 18 years 
old or older, residing in the same metropolitan area of 
Murcia and exclusively having no lifetime SUD. Details 
of the PEGASUS-Murcia project protocol, sampling 
frame, selection and weighting procedures have been 
described elsewhere.35 Briefly, the eligible population was 
all non-institutionalised people aged 18 or older and were 
interviewed between June 2010 and May 2012. A stratified 
multistage clustered probability random sample design 
was used. Overall, PEGASUS comprised a total of 2621 
participants (overall response rate of 67.4%) interviewed 
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by trained lay interviewers using a structured diagnostic 
interview.36
The final sample included 142 cases receiving the treat-
ment for SUDs associated with use of either alcohol 
(n=81, 57.0%), opioids (n=9, 6.3%) or cocaine (n=52, 
36.6%). They were compared with a sample of 531 
controls randomly selected among those participants of 
PEGASUS-Murcia project with no lifetime SUDs (~35% 
of 1456 eligible controls). Overall, a subsample of 114 
cases (80.3%) and 329 controls (62%) provided buccal 
swabs for DNA isolation and posterior SLC6A4 genotype 
analysis.
sociodemographic variables
Sociodemographic variables evaluated in this study were: 
age at interview; sex; declared race (white/Caucasian or 
non-white/non-Caucasian); completed years of educa-
tion (none, primary or basic: 0–11 years; secondary or 




A revised version of the Composite International Diag-
nostic Interview (CIDI 3.0, hereafter referred to as the 
CIDI) adapted for use in Spain was used.37 Briefly, the 
CIDI is a structured interview designed by WHO for the 
purpose of ascertaining diagnoses of mental disorders for 
international comparative epidemiological research.38 
The number of lifetime mental disorders according 
to Diagnostic and Statistical Manual of Mental Disor-
ders) DSM-IV diagnostic criteria (ie, major depression, 
mania, hypomania, bipolar I and II, dysthymia, post-trau-
matic stress disorder (PTSD) and other disorders such as 
attention deficit, conduct and oppositional defiant disor-
ders) was determined. The evaluation of SUDs, including 
alcohol and drug abuse and/or dependence disorders, 




The CIDI includes a specific section on CAs that assesses 
12 dichotomously scored CAs experienced prior the age 
of 18 with retrospective self-reports (for a more compre-
hensive description, see Kessler et al39). Briefly, CAs have 
been described to be highly interrelated and, based on a 
published factor analysis, were categorised in two mean-
ingful groups: (1) ‘maladaptive family functioning’ (MFF) 
(that included four types of parental maladjustment—
mental illness, substance misuse, criminality and violence 
and three types of maltreatment—physical abuse, sexual 
abuse and neglect), and (2) ‘other CAs’ (covering five 
types of adversities: parental death, parental divorce, 
other parental loss, serious physical illness and family 
economic adversity). This instrument39 has been used in 
a number of international general population epidemio-
logical studies.40 41
Genotyping
Biological samples of oral mucosal epithelium were 
provided by participants on completion of the interview. 
Samples were collected in sterile 1.5 mL tubes, regis-
tered, processed and stored at Plataforma Biobanco de 
Murcia (BIOBANC-MUR)  (Instituto Murciano de Inves-
tigación Biosanitaria Virgen de la Arrixaca (IMIB-Ar-
rixaca) Biobank; Spanish Biobanks Registry number: 
B.0000859, partner of Spanish Biobanks Platform Insti-
tuto de Salud Carlos III (ISCIII): PT17/0015/0038; 
http://www. biobanco. imib. es). Genomic DNA was 
isolated from buccal swabs using QIAamp DNA Blood 
Mini Kit (QIAGEN), according to the manufactur-
er’s instructions, and was performed automatically in a 
QIAcube system (QIAGEN) to minimise the variability 
associated with manual handling. SLC6A4 gene keeps a 
variable number of tandem repeat polymorphisms in the 
transcription control region of the gene, which is located 
approximately 1 kb upstream from the transcription 
start site. Three polymorphisms of the SLC6A4 promoter 
(5-HTTLPR) were genotyped in two steps: first, PCR 
was carried out; second, the restriction fragment length 
polymorphism method was developed. The primers used 
to perform the PCR have been previously described42: 
sense- ATCG CTCC TGCA TCCC CCATTAT and antisense- 
GAGG TGCA GGGG GATG CTGGAA. Briefly, 25 µl reaction 
included 50 ng genomic DNA, 1× amplification buffer, 
0.2 mM dNTPs (deoxynucleotide tryphosphates) , 1.5 mM 
MgSO4, 0.2 µM of each primer, 1 unit Platinum Taq PCRx 
polymerase (Invitrogen) and 1× PCR enhancer owing to 
the high GC content in the polymorphism region. The 
reaction was initially heated to 95°C (5 min), followed 
by 35 cycles of 95°C (35 s), 60°C (30 s) and 68°C (30 s) 
and a final elongation step of 72°C (5 min). To distin-
guish between S (103 bp) and L (146 bp) alleles, PCR 
product reactions were analysed by size determination on 
a QIAxcel Advanced System (QIAGEN) by high-resolu-
tion capillary electrophoresis. As a result of biallelic geno-
typing, individuals were genotyped as S/S, S/L or L/L.
Afterwards, fast HpaII restriction enzyme digestion 
(Thermoscientific) was carried out for genotyping SNP 
rs25531 according to the manufacturer’s instructions. 
This SNP consists in the presence of adenine (A) or 
guanine (G), being digested in the last case. Final digested 
products were visualised on a QIAexcel, and individuals 
were genotyped as S/S, S/LA, S/LG, LA/LA, LA/LG and LG/LG. 
Given that the expression of LG allele was suggested to be 
similar to the S allele,20 the triallelic classification (S, LG, 
LA) arranged S/S, S/LG and LG/LG individuals as S’S’, and 
S/LA and LA/LG individuals as S’L’ and LA/LA individuals as 
L’ L’. The product sizes after digestion are: S (103 bp), LA 
(146 bp) and LG (83 bp, 63 bp). As a quality control of the 
genetic procedures, all genetic analyses were performed 
similarly, blinded to the case-control status of the partic-
ipants and, finally, 37 cases (32.5%) also provided blood 
samples, so that it was possible to isolate DNA and to 
genotype the 5-HTTLPR polymorphisms from both 
origins with 100% of concordance.
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statistical methods
Risk associated to the exposure to CAs was estimated in 
the whole sample, whereas the effect associated to the 
5-HTTLPR polymorphism and potential G×E interac-
tions were evaluated only in the subgroup of participants 
with available genetic information. Student’s t-tests or χ2 
tests for continuous or categorical variables, respectively, 
were used to explore differences in sociodemographic 
characteristics, number of lifetime mental disorders and 
CAs between those participants with and without genetic 
data. Calculations for deviation from the Hardy-Weinberg 
equilibrium were performed using the χ2 tests of good-
ness of fit for biallelic and triallegic genotype frequen-
cies in controls. A series of simple and multiple logistic 
regression models with case/control status as the depen-
dent variable were built to estimate the associated risk. To 
explore the association with the type of 5-HHTLPR poly-
morphism classification, two genetic approaches were 
used with the number of S’ or S alleles (triallelic or bial-
lelic frequency model, respectively). As the type of inher-
itance of the 5-HTTLPR polymorphism is not yet known, 
the exploratory analyses were repeated assuming a trial-
lelic or biallelic dominant heritage for the short allele (at 
least one S’ or S allele), or a recessive heritage (S’S’ vs L’_, 
or SS vs L_). Crude and adjusted ORs and their 95% CIs 
were computed.
Finally, to explore the presence of G×E interactions, 
independent sequential multivariable logistic regression 
models were built including, in a hierarchical manner, 
the previously defined interaction terms formed with the 
product of the 5-HTTLPR genotype with the exposure to 
CAs and adjusted by all variables previously mentioned. 
The relative excess risk due to interaction as a measure 
of G×E interactions on the additive scale with logistic 
regression43 and bootstrapping to estimate 95% CI was 
performed using the R statistical software. All other anal-
yses were conducted using SPSS (V.20.0). All statistics 
used two-sided tests with alpha level of 0.05. An a priori 
decision was made not to correct for multiple testing as 
conditions in which a correction for multiple testing is 
necessary are still a matter of controversy. It has been 
suggested that in exploratory analyses of a genetically 
complex trait in which the relationship between geno-
type and phenotype has not yet been established,11 17–19 44 
multiple test adjustments are not strictly required45 since 
they may increase the likelihood that actual effects would 
be missed (type II error rates).46
rEsults
Table 1 describes the sociodemographic characteristics 
of the total sample (n=673) and of the subsample with 
DNA (n=443). Genotype frequencies in controls did not 
deviate from those predicted by the Hardy-Weinberg 
equilibrium, both in the triallelic (χ2=2.43, p=0.119) and 
the biallelic classification (χ2=0.51, p=0.473). All CAs were 
significantly more frequent among cases, except for the 
exposure to a life-threatening physical illness (table 2). 
There were no differences in any variable between 
those cases and controls with or without DNA sample 
(see online supplementary file 1), except for a history of 
parental mental illness.
Childhood adversities
The exposure to CAs was associated with a higher risk of 
substance abuse disorders in the whole sample in both 
models (table 3). A similar pattern was obtained for each 
independent CA, except for a history of a parental loss 
and a life-threatening physical illness (table 4). Among 
those statistically significant, sexual abuse was inde-
pendently associated with the highest risk (OR=11.58, 
95% CI 2.23 to 60.04) and exposure to other parental loss 
associated with the lowest risk (2.56, 2.09 to 7.65). The 
risk associated with exposure to CAs when adjusted by the 
number of S’ and S alleles was even higher than the unad-
justed risk (table 3 and see online supplementary file 2, 
respectively) and a similar pattern was observed when the 
different CAs were analysed independently (table 4).
the 5-httlPr polymorphism
The number of S’ and S alleles was significantly different 
between cases and controls (table 1), but the associ-
ated risk was non-significant in the multivariable logistic 
regression (table 3). When analyses focused on those 
without lifetime mental disorders, the associated risk 
remained significant for the number of S’ and S alleles 
(1.95, 1.09 to 3.54 for the triallelic and 2.14, 1.22 to 3.75 
for the biallelic classification). Different G×E interaction 
terms were entered in the multivariable but none of them 
reached significance, either with the triallelic or with the 
biallelic classification of the polymorphism.
Table 5 explores the association of the different forms 
of heritage of the 5-HTTLPR polymorphism in general 
and by the type of substance for which cases were being 
treated. When adjusted by all other variables, only the 
recessive triallelic (S’S’+S’L’ vs S’S’) and biallelic (SL+LL 
vs SS) heritage remained significant. When the analyses 
were restricted to explore the type of substance they were 
in treatment for (alcohol, opioids or cocaine), only those 
in treatment for alcohol-related problems with two S’S’ or 
SS alleles (recessive triallelic or biallelic heritage, respec-
tively) and the frequency biallelic model (the number of 
the S alleles) were significantly associated. Again, none of 
the G×E interaction terms created with the different types 
of heritages was significant (neither in the multiplicative, 
nor in the additive scales, data not shown).
DIsCussIOn
The aims of this study were to evaluate the association of 
CAs and the 5-HTTLPR polymorphism with SUD in adults 
and to explore whether the 5-HTTLPR moderates the 
risk of CAs in a G×E interaction model. First, exposure to 
CAs was associated with higher risk of SUDs. Second, our 
results suggest a main effect of the 5-HTTLPR polymor-
phism on SUDs. Though there were significant differences 
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in the triallelic and biallelic frequencies of both groups, 
the association disappeared when controlling for CAs, 
sociodemographic variables and the number of lifetime 
mental disorders. Lastly, our results do not support a G×E 
interaction between CAs and 5-HTTLPR. These results 
are discussed below.
Our finding that exposure to CAs increases the risk of 
SUDs in adults is consistent with the existing literature. 
Exposure to CAs has been associated with the increased 
risk of addictive behaviours, both in youth47 and in 
adulthood.48 This risk seems to be non-specific as the 
exposure to CAs also increases the risk of other mental 
disorders40 49–54 as well as the risk of other non-psychi-
atric conditions, such as diabetes, asthma and cardiovas-
cular disease.55–59 CAs have been suggested to be more 
important from a public health point of view than all 
common mental disorders taken together.60
The recessive model of heritage increased the risk of 
SUDs, especially in the subgroup treated for an alco-
hol-related disorder. Nevertheless, this specificity should 
be interpreted with caution due to the smaller number 
of participants with opioid-related or cocaine-related 
disorders. Of note, the association of 5-HTTLPR with 
SUDs was significant in multivariable analyses restricted 
to participants without any lifetime mental disorders. 
This result suggests a mediating effect of previous mental 
disorders on the association between 5-HTTLPR and 
SUDs and highlights the importance of measuring other 
mental disorders related to 5-HTTLPR polymorphism 
when analysing its relation to SUDs. Attention should be 
paid to variables included in multivariable logistic regres-
sion models. Our results are in accordance with previous 
studies. The homozygote genotype SS has been shown 
to be significantly related to heroin dependence61 and 
the S allele to alcohol dependence.25 62 63 A meta-analysis 
including alcohol, heroin, cocaine, and methamphet-
amine dependence showed a significantly stronger asso-
ciation of the dominant biallelic model (SS+SL vs LL),11 
though the most recent meta-analysis focused on alcohol 
dependence did not find an overall association.19 Only a 
few studies have analysed the triallelic functional classi-
fication with conflicting results. Alleles with low SLC6A4 
promoter activity (S’S’) predicted comorbid alcohol, 
cocaine and heroin dependence but not alcohol depen-
dence alone.23 The triallelic polymorphism was associ-
ated with early onset in men with alcohol dependence 
but a non-significant trend in the opposite direction was 
described in women.24
Contrary to expectations, the results of the exploratory 
analysis do not support a G×E interaction between CAs 
and 5-HTTLPR. Very few studies focused on this inter-
action have been published to date. Adolescents with 
the LS variant who came from families with conflicting 
relationships had an increased risk of problems with 
alcohol.32 The S allele interacted with physical, sexual 
and emotional abuse, neglect and exposure to domestic 
violence to predict early alcohol use in adolescents31 and 
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susceptibility to use alcohol, cocaine and cannabis.29 In 
contrast, there was no G×E interaction between the bial-
lelic 5-HTTLPR polymorphisms with childhood neglect 
on alcohol use problems30 and between the triallelic 
polymorphisms in a sample of alcohol-dependent adults 
with no current comorbid mental disorders in relation to 
smoking.64 College students homozygous for the S allele 
who have experienced multiple negative life events are 
at greater risk for alcohol consumption and drug use.25 
The S’ allele carriers were more susceptible to the effects 
of a history of family conflicts on alcohol misuse26 and to 
the effects of greater residential instability on substance 
use across ages 10–24 years.27 Nevertheless, our results 
should be interpreted with caution as many other and 
not yet well-known factors may contribute to the devel-
opment of complex brain disorders such as SUDs. For 
example, the G×E interactions influencing SUDs may be 
more robust at specific periods, such as younger ages.65 
Other gene–gene interactions may obscure the potential 
role of specific genes in the aetiology of substance disor-
ders.66 Lastly, epigenetic mechanisms may modify gene 
expression and modulate the development of SUDs.67 
To the best of our knowledge, only one study has directly 
analysed the epigenetic changes of the 5-HTTLPR in a 
case-control study with no differences between alcohol-de-
pendent and control participants.68 However, additional 
research is needed on this topic as the latter study has 
important limitations, including a small sample size (only 
27 patients and 15 controls) and analyses solely focused 
on one (the methylation patterns) among other known 
epigenetic mechanisms.67
Several limitations deserve consideration. First, and 
most importantly, it is reasonable to consider that statis-
tical analyses may have been underpowered to detect a 
small G×E interaction. If this is the case, additional asso-
ciation studies with larger samples or the combination 
of similar studies in future meta-analyses of G×E interac-
tions will contribute to clarify this point.69 Second, only 
a subgroup of participants provided biological samples. 
However, those who provided the DNA sample did not 
differ from those who did not in terms of sociodemo-
graphic variables, number of lifetime mental disorders, 
principal substance of abuse and exposure to CAs. Third, 
a potential recall bias cannot be ruled out as CAs were 
assessed retrospectively. However, this bias is likely not 
to have affected the results presented as CAs that were 
evaluated through an identical retrospective structured 
questionnaire in both cases and controls.70 Fourth, 
relatedness among participants has not been assessed, 
but it is highly unlikely that this possibility would have 
affected the results as case-control samples have been 
drawn from non-isolated populations. Fifth, the selection 
of cases from clinical treatment settings may have intro-
duced a selection bias. As a result, caution is warranted 
in the generalisation of the results to other individuals 
who are not receiving formal treatment for their disor-
ders. Finally, psychiatric diagnoses were determined 
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moderate-to-excellent concordance has been described 
for most mental disorders in blind clinical reappraisal 
studies.71 72
A major strength of the study is related to measures 
introduced in the design to address some of the limitations 
described in previous studies.19 First, an adequate control 
group was randomly selected among those without any 
SUDs from the PEGASUS-Murcia project and a compre-
hensive number of variables were controlled for in the 
multivariable analyses.35 36 Second, a careful screening 
for other mental disorders related to the same polymor-
phism15 73 74 was performed using a structured clinical 
interview.37 Finally, biallelic and triallelic approaches 
to the 5-HTTLPR polymorphism were tested in the 
subsample of participants with DNA. Quality genetic 
controls were performed and the 5-HTTLPR polymor-
phism frequencies in controls were in accordance to the 
Hardy-Weinberg equilibrium.
In summary, the present study confirms the risk effect 
of CAs on SUDs and adds new evidence to support the 
role of the 5-HTTLPR polymorphism. Further studies 
and future meta-analyses focused on G×E interactions 
are needed to clarify these nature–nurture interactions 
as such findings might have important implications in the 
prevention and treatment of SUDs.75
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